Health & Public Health
Pancreatic cancer drug Rasonque approved by FDA
The US Food and Drug Administration approved Rasonque, a pancreatic cancer treatment developed by US startup Revolution Medicines, the agency announced on Aug. 26.
A clinical trial found the drug could double survival time for certain patients, according to the announcement.
Pancreatic cancer is described as one of the deadliest forms of the disease.
Update
The approved treatment has the brand name Rasonque.
Rasonque was developed by US startup Revolution Medicines.
A clinical trial found the drug could double survival time for certain patients.
Source note: AFP news report published on 26 August 2026 at 17:37:30 UTC.
Uncertainty notes
The supplied information does not specify which patients may benefit or give detailed trial data.
Source
AFP news report published on .